NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
BELTSVILLE, Md., Oct. 05, 2022 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company…
BELTSVILLE, Md., Oct. 05, 2022 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company…
TNG260 is in preclinical development as a first-in-class CoREST deacetylase inhibitor for the treatment of…
Oral Presentation of C-144-01 Trial Cohorts 2 and 4 SAN CARLOS, Calif., Oct. 05, 2022…
TORONTO and HOUSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA…
ZUG, Switzerland and BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
Five poster presentations to include preclinical data describing new T-cell reprogramming technology being incorporated in…
BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted…
MILAN, Italy and NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) — Genenta Science (NASDAQ: GNTA),…
BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company…
NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical…
CAMBRIDGE, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company…
A poster evaluating comprehensive correlative science findings from the AFM24 monotherapy phase 1 study (AFM24-101)…
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX…
Abstracts highlight Senti Bio’s continued progress in applying gene circuits to improve the cytotoxicity and…
BERKELEY, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) — Valitor, a biotechnology company engineering better medicines to…
Interim Analysis Planned for Q1 2023 WILMETTE, Ill., Oct. 05, 2022 (GLOBE NEWSWIRE) — Monopar…
BOTHELL, Wash., Oct. 05, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that…
Abstract titles to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting…
SAN DIEGO, Oct. 05, 2022 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage…
Clinical data in nine cancer indications from trial with 264 patients accrued Plenary discussion relating…